YZG-331

Clinical data
Other names	N6-[(S)-1-(Phenyl)propyl]adenosine
Drug class	Adenosine receptor agonist; Sedative; Hypnotic
ATC code	None
Identifiers
IUPAC name (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(1S)-1-phenylpropyl]amino]purin-9-yl]oxolane-3,4-diol
PubChem CID	54282370
Chemical and physical data
Formula	C19H23N5O4
Molar mass	385.424 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC[C@@H](C1=CC=CC=C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
InChI InChI=1S/C19H23N5O4/c1-2-12(11-6-4-3-5-7-11)23-17-14-18(21-9-20-17)24(10-22-14)19-16(27)15(26)13(8-25)28-19/h3-7,9-10,12-13,15-16,19,25-27H,2,8H2,1H3,(H,20,21,23)/t12-,13+,15+,16+,19+/m0/s1 Key:RRRLUFHDFDNPMZ-BPAMBQHCSA-N

YZG-331, also known as N⁶-[(S)-1-(phenyl)propyl]adenosine, is an adenosine receptor agonist which is or was under investigation for the potential treatment of insomnia.^[1][2][3]

Pharmacology

The drug appears to act through the adenosine A₁ and A_2A receptors.^[3] It produces sedative and hypnotic effects and hypolocomotion in animals.^[3] The drug is orally active and crosses the blood–brain barrier, although its intestinal absorption and central permeability may be reduced by its P-glycoprotein substrate activity.^[4][5] It is a synthetic derivative of adenosine and of N⁶-(4-hydroxybenzyl)adenine riboside (NHBA).^[5][3] The latter compound is found in the traditional Chinese medicinal herb Gastrodia elata.^[5][3]

Development

YZG-331 was first described in the scientific literature by at least 2014.^[6] As of 2025, it has reached the preclinical research stage of development.^[1]

See also

• List of investigational insomnia drugs

References